164 related articles for article (PubMed ID: 33825059)
1. Stereotactic Radiofrequency Ablation of Breast Cancer Liver Metastases: Short- and Long-Term Results with Predicting Factors for Survival.
Schullian P; Johnston E; Laimer G; Putzer D; Eberle G; Scharll Y; Ianetti-Hackl C; Bale R
Cardiovasc Intervent Radiol; 2021 Aug; 44(8):1184-1193. PubMed ID: 33825059
[TBL] [Abstract][Full Text] [Related]
2. Stereotactic radiofrequency ablation (SRFA) for recurrent colorectal liver metastases after hepatic resection.
Schullian P; Johnston EW; Putzer D; Laimer G; Waroschitz G; Braunwarth E; Amann A; Maglione M; Bale R
Eur J Surg Oncol; 2021 Apr; 47(4):866-873. PubMed ID: 33032865
[TBL] [Abstract][Full Text] [Related]
3. Stereotactic radiofrequency ablation as first-line treatment of recurrent HCC following hepatic resection.
Schullian P; Laimer G; Putzer D; Levy E; Braunwarth E; Stättner S; Bale R
Eur J Surg Oncol; 2020 Aug; 46(8):1503-1509. PubMed ID: 32222261
[TBL] [Abstract][Full Text] [Related]
4. Stereotactic Radiofrequency Ablation for Breast Cancer Liver Metastases.
Bale R; Richter M; Dünser M; Levy E; Buchberger W; Schullian P
J Vasc Interv Radiol; 2018 Feb; 29(2):262-267. PubMed ID: 29273283
[TBL] [Abstract][Full Text] [Related]
5. Stereotactic Radiofrequency Ablation for Metastatic Melanoma to the Liver.
Bale R; Schullian P; Schmuth M; Widmann G; Jaschke W; Weinlich G
Cardiovasc Intervent Radiol; 2016 Aug; 39(8):1128-35. PubMed ID: 27055850
[TBL] [Abstract][Full Text] [Related]
6. Safety and efficacy of stereotactic radiofrequency ablation for very large (≥8 cm) primary and metastatic liver tumors.
Schullian P; Johnston EW; Putzer D; Eberle G; Laimer G; Bale R
Sci Rep; 2020 Jan; 10(1):1618. PubMed ID: 32005871
[TBL] [Abstract][Full Text] [Related]
7. Stereotactic radiofrequency ablation of subcardiac hepatocellular carcinoma: a case-control study.
Schullian P; Johnston EW; Putzer D; Eberle G; Laimer G; Bale R
Int J Hyperthermia; 2019; 36(1):876-885. PubMed ID: 31462110
[No Abstract] [Full Text] [Related]
8. Technical efficacy and local recurrence after stereotactic radiofrequency ablation of 2653 liver tumors: a 15-year single-center experience with evaluation of prognostic factors.
Schullian P; Laimer G; Johnston E; Putzer D; Eberle G; Scharll Y; Widmann G; Kolbitsch C; Bale R
Int J Hyperthermia; 2022; 39(1):421-430. PubMed ID: 35227136
[TBL] [Abstract][Full Text] [Related]
9. Percutaneous stereotactic radiofrequency ablation of colorectal liver metastases.
Bale R; Widmann G; Schullian P; Haidu M; Pall G; Klaus A; Weiss H; Biebl M; Margreiter R
Eur Radiol; 2012 Apr; 22(4):930-7. PubMed ID: 22071776
[TBL] [Abstract][Full Text] [Related]
10. Percutaneous CT-guided radiofrequency ablation for patients with extrahepatic oligometastases of hepatocellular carcinoma: long-term results.
Mu L; Sun L; Pan T; Lyu N; Li S; Li X; Wang J; Xie Q; Deng H; Zheng L; Peng J; Shen L; Fan W; Wu P; Zhao M
Int J Hyperthermia; 2018 Feb; 34(1):59-67. PubMed ID: 28540809
[TBL] [Abstract][Full Text] [Related]
11. Frequency and risk factors for major complications after stereotactic radiofrequency ablation of liver tumors in 1235 ablation sessions: a 15-year experience.
Schullian P; Johnston E; Laimer G; Putzer D; Eberle G; Amann A; Effenberger M; Maglione M; Freund MC; Loizides A; Bale R
Eur Radiol; 2021 May; 31(5):3042-3052. PubMed ID: 33125554
[TBL] [Abstract][Full Text] [Related]
12. Long-term outcomes and prognostic analysis of percutaneous radiofrequency ablation in liver metastasis from breast cancer.
Bai XM; Yang W; Zhang ZY; Jiang AN; Wu W; Lee JC; Chen MH; Yan K
Int J Hyperthermia; 2019 Jan; 35(1):183-193. PubMed ID: 30200791
[TBL] [Abstract][Full Text] [Related]
13. Stereotactic radiofrequency ablation of a variety of liver masses in children.
Hetzer B; Vogel GF; Entenmann A; Heil M; Schullian P; Putzer D; Meister B; Crazzolara R; Kropshofer G; Salvador C; Straub S; Karall D; Niederwanger C; Cortina G; Janecke A; Freund-Unsinn K; Maurer K; Schweigmann G; Oberhuber G; Renz O; Schneeberger S; Müller T; Bale R
Int J Hyperthermia; 2020; 37(1):1074-1081. PubMed ID: 32954876
[TBL] [Abstract][Full Text] [Related]
14. Stereotactic radiofrequency ablation of tumors at the hepatic venous confluence.
Schullian P; Johnston E; Laimer G; Scharll Y; Putzer D; Eberle G; Kolbitsch C; Amann A; Stättner S; Bale R
HPB (Oxford); 2022 Jul; 24(7):1044-1054. PubMed ID: 34887174
[TBL] [Abstract][Full Text] [Related]
15. Breast cancer liver metastases: US-guided percutaneous radiofrequency ablation--intermediate and long-term survival rates.
Meloni MF; Andreano A; Laeseke PF; Livraghi T; Sironi S; Lee FT
Radiology; 2009 Dec; 253(3):861-9. PubMed ID: 19709994
[TBL] [Abstract][Full Text] [Related]
16. Stereotactic radiofrequency ablation (SRFA) of liver lesions: technique effectiveness, safety, and interoperator performance.
Widmann G; Schullian P; Haidu M; Bale R
Cardiovasc Intervent Radiol; 2012 Jun; 35(3):570-80. PubMed ID: 21671150
[TBL] [Abstract][Full Text] [Related]
17. Salvage RFA in patients with intrahepatic recurrence after major hepatic surgery for colorectal cancer liver metastases: mid-term outcome.
Zimmermann M; Pedersoli F; Schulze-Hagen M; Lurje G; Isfort P; Kuhl C; Bruners P
Eur Radiol; 2020 Feb; 30(2):1221-1227. PubMed ID: 31493210
[TBL] [Abstract][Full Text] [Related]
18. Stereotactic radiofrequency ablation as a valid first-line treatment option for hepatocellular adenomas.
Laimer G; Schullian P; Scharll Y; Putzer D; Eberle G; Oberhuber G; Bale R
Int J Hyperthermia; 2022; 39(1):780-787. PubMed ID: 35654476
[TBL] [Abstract][Full Text] [Related]
19. Simultaneous Stereotactic Radiofrequency Ablation of Multiple (≥ 4) Liver Tumors: Feasibility, Safety, and Efficacy.
Schullian P; Putzer D; Eberle G; Laimer G; Bale R
J Vasc Interv Radiol; 2020 Jun; 31(6):943-952. PubMed ID: 32414570
[TBL] [Abstract][Full Text] [Related]
20. Stereotactic radiofrequency ablation of unresectable intrahepatic cholangiocarcinomas: a retrospective study.
Haidu M; Dobrozemsky G; Schullian P; Widmann G; Klaus A; Weiss H; Margreiter R; Bale R
Cardiovasc Intervent Radiol; 2012 Oct; 35(5):1074-82. PubMed ID: 22006031
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
